In SAVANNAH, a multicentre phase Ib single arm study, the investigators are exploring the efficacy of 28-day continuative combined therapy with osimertinib (80 mg oral OD) and savolitinib, a c-MET selective inhibitor (300 mg oral OD or 300 mg oral BID or 600 mg oral OD), in patients with EGFR mutation-positive locally advanced or metastatic NSCLC with MET-driven resistance to osimertinib. Here, MET is linked to non-small cell lung carcinoma.